{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:32:38Z","timestamp":1791106358901,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1157,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Peginterferon (PEG-IFN) treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) results in HBeAg loss in 30% of patients, but clearance of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) from serum is less often achieved. We investigated whether the presence of precore (PC) and basal core promoter (BCP) mutants before PEG-IFN treatment affects serological and virological response. A total of 214 HBeAg-positive CHB patients treated with PEG-IFN\u00b1lamivudine for 52 weeks in a global randomized trial were classified at baseline as wildtype (WT) or non-WT (detectable mutants at PC\/BCP) by line-probe assay. Response was assessed at 6 months posttreatment and through long-term follow-up (LTFU). Mutants were detected in 64% of patients, in varying frequencies across HBV genotypes A through D. Patients with WT had higher baseline HBV DNA, HBeAg, and HBsAg levels than patients with non-WT. Patients with WT were more likely to achieve HBeAg loss with HBV DNA &lt;10,000 copies\/mL (response, 34 versus 11%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and HBsAg clearance (18 versus 2%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) at week 78 than non-WT patients. Among WT patients who achieved HBeAg clearance at week 78, 78% had undetectable HBV DNA and 61% achieved HBsAg clearance at LTFU (versus 26% and 15% in non-WT patients,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001 for both). The presence of WT virus at baseline was an independent predictor of response (odds ratio [OR] 2.90, 95% confidence interval [CI]: 1.15-7.31,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.023) and HBsAg clearance (OR 5.58, 95% CI: 1.26-24.63,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013) and patients with non-A genotypes with detectable mutants had a low probability of response.\n                      <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                      The presence of only WT virus at baseline is a strong predictor of response (HBeAg loss with HBV DNA &lt;10,000 copies\/mL) to PEG-IFN for HBeAg-positive CHB. Patients with detectable PC and\/or BCP mutants have a lower probability of response and are less optimal candidates for PEG-IFN therapy. (HEPATOLOGY 2012;56:67\u201375)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.25636","type":"journal-article","created":{"date-parts":[[2012,2,6]],"date-time":"2012-02-06T01:05:09Z","timestamp":1328490309000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":74,"title":["Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B"],"prefix":"10.1097","volume":"56","author":[{"given":"Milan J.","family":"Sonneveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rijckborst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny E.","family":"Heathcote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Senturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan D.","family":"Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20241201","first-page":"227242","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B.","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"R2-9-20241201","doi-asserted-by":"crossref","first-page":"14861500","DOI":"10.1056\/NEJMra0801644","article-title":"Hepatitis B virus infection.","volume":"359","author":"Dienstag","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-9-20241201","first-page":"507539","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"R4-9-20241201","doi-asserted-by":"crossref","first-page":"168174","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma.","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"R5-9-20241201","first-page":"8490","article-title":"Longterm outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years.","volume":"57","author":"Fattovich","year":"2008","journal-title":"Gut"},{"key":"R6-9-20241201","doi-asserted-by":"crossref","first-page":"123129","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa2b alone or in combination with lamivudine for HBeAgpositive chronic hepatitis B: a randomised trial.","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"R7-9-20241201","doi-asserted-by":"crossref","first-page":"491498","DOI":"10.1053\/j.gastro.2010.03.059","article-title":"Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.","volume":"139","author":"Reijnders","year":"2010","journal-title":"Gastroenterology"},{"key":"R8-9-20241201","doi-asserted-by":"crossref","first-page":"459467","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after longterm followup of HBeAgpositive patients treated with peginterferon alpha2b.","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"R9-9-20241201","doi-asserted-by":"crossref","first-page":"420424","DOI":"10.1136\/gut.52.3.420","article-title":"Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.","volume":"52","author":"van Nunen","year":"2003","journal-title":"Gut"},{"key":"R10-9-20241201","doi-asserted-by":"crossref","first-page":"19451953","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa2b treatment at 5 years in patients with hepatitis B e antigenpositive chronic hepatitis B.","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"},{"key":"R11-9-20241201","doi-asserted-by":"crossref","first-page":"208212","DOI":"10.1007\/s10620-010-1255-9","article-title":"Longterm effect of interferon therapy in patients with HBeAg positive chronic hepatitis B infection.","volume":"56","author":"Senturk","year":"2011","journal-title":"Dig Dis Sci"},{"key":"R12-9-20241201","doi-asserted-by":"crossref","first-page":"716725","DOI":"10.1002\/hep.510310323","article-title":"Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B.","volume":"31","author":"Erhardt","year":"2000","journal-title":"Hepatology"},{"key":"R13-9-20241201","doi-asserted-by":"crossref","first-page":"13791392","DOI":"10.1128\/JVI.01902-08","article-title":"A mechanism to explain the selection of the hepatitis e antigennegative mutant during chronic hepatitis B virus infection.","volume":"83","author":"Frelin","year":"2009","journal-title":"J Virol"},{"key":"R14-9-20241201","doi-asserted-by":"crossref","first-page":"199204","DOI":"10.1016\/j.jcv.2007.04.008","article-title":"Presence of hepatitis B virus core promoter mutations preseroconversion predict persistent viral replication after HBeAg loss.","volume":"39","author":"Ferns","year":"2007","journal-title":"J Clin Virol"},{"key":"R15-9-20241201","doi-asserted-by":"crossref","first-page":"14581465","DOI":"10.1053\/j.gastro.2007.08.039","article-title":"Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B.","volume":"133","author":"Chu","year":"2007","journal-title":"Gastroenterology"},{"key":"R16-9-20241201","doi-asserted-by":"crossref","first-page":"12511257","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa2b for hepatitis B e antigenpositive chronic hepatitis B using ontreatment hepatitis B surface antigen decline.","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"R17-9-20241201","doi-asserted-by":"crossref","first-page":"36993705","DOI":"10.1128\/JCM.41.8.3699-3705.2003","article-title":"Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants.","volume":"41","author":"Hussain","year":"2003","journal-title":"J Clin Microbiol"},{"key":"R18-9-20241201","doi-asserted-by":"crossref","first-page":"28972901","DOI":"10.1128\/JCM.38.8.2897-2901.2000","article-title":"Development of a quantitative realtime detection assay for hepatitis B virus DNA and comparison with two commercial assays.","volume":"38","author":"Pas","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R19-9-20241201","doi-asserted-by":"crossref","first-page":"20022009","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigenpositive chronic hepatitis B to peginterferonalfa.","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"R20-9-20241201","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3851\/IMP1887","article-title":"Durable hepatitis B surface antigen decline in hepatitis B e antigenpositive chronic hepatitis B patients treated with pegylated interferon2b: relation to response and HBV genotype.","volume":"17","author":"Sonneveld","year":"2012","journal-title":"Antivir Ther"},{"key":"R22-9-20241201","doi-asserted-by":"crossref","first-page":"335352","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"R23-9-20241201","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R24-9-20241201","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1128\/JCM.40.1.16-21.2002","article-title":"Precore stop mutant in HBeAgpositive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAgtoantiHBe seroconversion.","volume":"40","author":"Chu","year":"2002","journal-title":"J Clin Microbiol"},{"key":"R25-9-20241201","doi-asserted-by":"crossref","first-page":"619628","DOI":"10.1053\/jhep.2003.50352","article-title":"Prevalence of HBV precorecore promoter variants in the United States.","volume":"38","author":"Chu","year":"2003","journal-title":"Hepatology"},{"key":"R26-9-20241201","doi-asserted-by":"crossref","first-page":"203210","DOI":"10.1177\/135965350901400206","article-title":"Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.","volume":"14","author":"Tseng","year":"2009","journal-title":"Antivir Ther"},{"key":"R27-9-20241201","doi-asserted-by":"crossref","first-page":"10551063","DOI":"10.1002\/jmv.20935","article-title":"Genetic characteristics of hepatitis B virus genotypes as a factor for interferoninduced HBeAg clearance.","volume":"79","author":"Hou","year":"2007","journal-title":"J Med Virol"},{"key":"R28-9-20241201","doi-asserted-by":"crossref","first-page":"12841289","DOI":"10.1002\/hep.1840120606","article-title":"Defects in the precore region of the HBV genome in patients with chronic hepatitis B after sustained seroconversion from HBeAg to antiHBe induced spontaneously or with interferon therapy.","volume":"12","author":"Takeda","year":"1990","journal-title":"Hepatology"},{"key":"R29-9-20241201","doi-asserted-by":"crossref","first-page":"428434","DOI":"10.1002\/hep.22065","article-title":"HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa2a for HBeAgpositive chronic hepatitis B.","volume":"47","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"R30-9-20241201","doi-asserted-by":"crossref","first-page":"454461","DOI":"10.1002\/hep.23722","article-title":"Early ontreatment prediction of response to peginterferon alfa2a for HBeAgnegative chronic hepatitis B using HBsAg and HBV DNA levels.","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"R31-9-20241201","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1016\/S1386-6532(01)00251-7","article-title":"The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation.","volume":"25","author":"Pas","year":"2002","journal-title":"J Clin Virol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.25636","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201207000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T09:11:51Z","timestamp":1733044311000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201207000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.25636","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717951200.793456500","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}